Effect of Single High-Dose Vitamin D3 Versus Placebo on Hospital Length of Stay in Children With Severe Pneumonia. (VIT-D-PNEUMONI)

November 9, 2026 updated by: Adeel Bashir, Shaheed Mohtarma Benazir Bhutto Institue of Trauma

Comparison of the Mean Hospital Length of Stay After Single High Dose of Vitamin D3 Versus Placebo in Children Presenting With Severe Pneumonia at DHQ Mirpur Azad Kashmir

Severe pneumonia is a major cause of morbidity and mortality among children and often requires hospitalization and prolonged medical care. Vitamin D plays an important role in immune regulation and inflammatory responses, and its supplementation may help improve outcomes in respiratory infections. However, evidence regarding its effectiveness in reducing the duration of hospital stay among children with severe pneumonia remains limited.

This randomized controlled trial will be conducted at the Department of Pediatrics, Divisional Headquarters Teaching Hospital, Mirpur, Azad Jammu and Kashmir, over six months after approval of the synopsis. A total of 114 children of either sex, aged 1-16 years, presenting with severe pneumonia will be enrolled through non-probability consecutive sampling. Patients with a history of tuberculosis, congenital heart disease, cleft lip or palate, bronchial asthma, upper airway abnormality, urinary tract infection, malaria, dengue, typhoid fever, or malnourishment will be excluded.

Eligible participants will be randomly allocated into two groups using sealed opaque envelopes. Group A will receive a single oral dose of 200,000 IU vitamin D3 dissolved in 10 mL of peanut oil, while Group B will receive 10 mL of peanut oil as placebo. Both preparations will be identical in color, taste, smell, consistency, and container. Participants will be followed until discharge. Hospital length of stay, defined as the period from admission to discharge, will be recorded for each patient. Data will be analyzed using SPSS version 20. Mean hospital length of stay will be compared between the two groups using an independent samples t-test, with p≤0.05 considered statistically significant.

The study aims to determine whether a single high dose of vitamin D3 reduces hospital length of stay compared with placebo in children presenting with severe pneumonia.

Study Overview

Detailed Description

Pneumonia remains one of the leading causes of morbidity and mortality among children, particularly those under five years of age. Severe pneumonia frequently requires hospitalization, prolonged medical care, and close monitoring. Several host, environmental, and infectious factors contribute to the development and severity of childhood pneumonia, including inadequate breastfeeding, low birth weight, malnutrition, exposure to indoor air pollution, overcrowding, and inadequate immunization. Viral and bacterial infections may also occur simultaneously, contributing to disease severity and clinical complications.

Vitamin D has an important role in regulating immune function and inflammatory responses involved in host defense against infections. It is also considered important for normal lung development and preservation of respiratory function. Previous observational studies have suggested an association between vitamin D deficiency and increased susceptibility to respiratory tract infections. Furthermore, research has explored the potential protective effects of vitamin D supplementation against respiratory infections in children and adults.

Although vitamin D supplementation is a relatively simple and potentially inexpensive intervention, its effectiveness in improving clinical outcomes among children hospitalized with severe pneumonia remains uncertain. Previous studies evaluating vitamin D supplementation in children with pneumonia have reported inconsistent findings. Therefore, further clinical research is required to determine whether vitamin D supplementation can improve recovery and reduce the duration of hospitalization in children presenting with severe pneumonia.

This randomized controlled trial will compare the mean hospital length of stay among children with severe pneumonia receiving a single high dose of vitamin D3 and those receiving placebo. The study will be conducted at the Department of Pediatrics, Divisional Headquarters Teaching Hospital, Mirpur, Azad Jammu and Kashmir, over six months after approval of the synopsis. A total of 114 children will be enrolled, with 57 participants allocated to each group. The sample size has been calculated using OpenEpi software, with a 5% level of significance and 90% power. The mean hospital length of stay in the vitamin D supplementation group and placebo group, based on the pilot study, was 4.90 ± 0.37 days and 5.12 ± 0.46 days, respectively. Non-probability consecutive sampling will be used to enroll eligible participants.

Children of either sex, aged 1-16 years, presenting with severe pneumonia will be included in the study. Severe pneumonia will be identified in children presenting with cough and/or difficulty in breathing of less than three weeks' duration along with one or more of the following findings: respiratory rate of 60 or more breaths per minute in children younger than 2 months, 50 or more breaths per minute in children aged 2-11 months, or 40 or more breaths per minute in children aged 12 months or older; lower chest wall indrawing; increased work of breathing indicated by recessions, grunting, or nasal flaring; oxygen saturation (SpO2) of 92% or less; or a new pulmonary infiltrate on chest radiograph appearing as an opacity with or without an air bronchogram.

Patients with a history of tuberculosis, congenital heart disease, cleft lip or palate, bronchial asthma, upper airway abnormality, urinary tract infection, malaria, dengue, typhoid fever, or malnourishment will be excluded from the study.

The study will be initiated after approval from the College of Physicians and Surgeons Pakistan and permission from the institutional ethical review committee. Written informed consent will be obtained from the parents or guardians of eligible children before enrollment. Demographic information, including age and gender, will be recorded for each participant. Eligible participants will be randomly allocated into two groups using sealed opaque envelopes bearing the labels A and B. Group A will receive a single oral dose of 200,000 IU of vitamin D3 dissolved in a 10 mL peanut oil solution, whereas Group B will receive 10 mL of peanut oil solution as placebo. Both preparations will be identical in color, taste, smell, consistency, and container.

All participants will be followed during their hospital stay. The duration of hospitalization will be recorded for each participant. Participants will be discharged when they demonstrate clinical improvement, stable vital signs, resolution of key danger signs, and the ability to tolerate oral medications. Hospital length of stay will be defined as the period from the date of hospital admission until the date of discharge and will be recorded in days for both groups.

Data will be collected using a structured proforma. In addition to demographic characteristics and assigned study group, information regarding family monthly income, maternal educational status, type of family (joint or nuclear), and type of residence (house or flat) will also be recorded. The primary outcome will be hospital length of stay, measured in days.

Data will be analyzed using Statistical Package for Social Sciences (SPSS), version 20. Mean and standard deviation will be calculated for quantitative variables, including age and hospital length of stay. The Kolmogorov-Smirnov test will be used to assess the distribution of quantitative variables. Normally distributed quantitative variables will be reported as mean ± standard deviation, whereas non-normally distributed variables will be presented as median and interquartile range. Frequencies and percentages will be calculated for qualitative variables, including gender, family monthly income, maternal educational status, type of family, and type of residence. The mean hospital length of stay will be compared between the two study groups using the independent samples t-test. Effect modifiers, including age, gender, family monthly income, maternal educational status, type of family, and type of residence, will be controlled through stratification. Post-stratification independent samples t-tests will be applied, with a p-value of 0.05 or less considered statistically significant.

The study aims to determine whether administration of a single high dose of vitamin D3 reduces hospital length of stay compared with placebo in children presenting with severe pneumonia. The findings may provide evidence regarding the potential role of vitamin D3 supplementation as an adjunctive intervention in the management of severe childhood pneumonia.

Study Type

Interventional

Enrollment (Estimated)

114

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 61100
        • Recruiting
        • Department of Pediatircs, Mohtarma Benazir Bhutto Shaheed Hospital, Mirpur AJ&K
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 16 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Children of either sex, between 1-16 years of age, presenting with severe pneumonia will be included in the study.

Exclusion Criteria:

  • Patients with history of tuberculosis.
  • Patients with history congenital heart disease and cleft lip/palate.
  • Patients with history of bronchial asthma.
  • Patients with upper airway abnormality.
  • Patients with history of UTI.
  • Patients with history of malaria, dengue and typhoid fever.
  • Patients with history of malnourishment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Vitamin D3 Group

Participants allocated to this group will receive a single high oral dose of 200,000 IU vitamin D3 dissolved in a 10 mL peanut oil solution. The intervention will be administered to children presenting with severe pneumonia. Participants will be followed during their hospital stay, and the duration from admission to discharge will be recorded in days.

Participants allocated to the vitamin D3 group will receive a single oral dose of 200,000 IU of vitamin D3 dissolved in a 10 mL peanut oil solution. The intervention will be administered to children presenting with severe pneumonia. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.

Placebo Comparator: Placebo Group

Participants allocated to this group will receive 10 mL of peanut oil solution as placebo. The placebo preparation will be identical to the vitamin D3 solution in color, taste, smell, consistency, and container. Participants will be followed during their hospital stay, and the duration from admission to discharge will be recorded in days.

Participants allocated to the placebo group will receive 10 mL of peanut oil solution orally. The placebo preparation will be identical to the vitamin D3 preparation in color, taste, smell, consistency, and container. Participants will be followed during their hospital stay, and hospital length of stay will be recorded from admission until discharge.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Hospital Length of Stay
Time Frame: From hospital admission until discharge (3-14 days).

Hospital length of stay will be measured in days, from the date of hospital admission until the date of discharge. The mean hospital length of stay will be compared between children receiving a single high dose of vitamin D3 and those receiving placebo.

From hospital admission until discharge (3-14 days).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • 9. Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. Cochrane Database Syst Rev 2018(7):23-33. 10. Singh N, Kamble D, Mahantshetti NS. Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children. Indian J Pediatr. 2019;86(12):1105-11. 11. Haugen J, Basnet S, Hardang IM, Sharma A, Mathisen M, Shrestha P, et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr Res. 2017 Dec;82(6):986-93. 12. Hurwitz JL, Jones BG, Penkert RR, Gansebom S, Sun Y, Tang L, et al. Low Retinol-Binding Protein and Vitamin D Levels Are Associated with Severe Outcomes in Children Hospitalized with Lower Respiratory Tract Infection and Respiratory Syncytial Virus or Human Metapneumovirus Detection. J Pediatr. 2017;187:323-7.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2026

Primary Completion (Estimated)

November 15, 2026

Study Completion (Estimated)

November 15, 2026

Study Registration Dates

First Submitted

November 3, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared with other researchers. No data-sharing plan has been established for this study. Study data will be used solely for the purposes of the approved research.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe